China has launched a three-year pilot scheme to loosen approvals for new drugs, the country's food and drug regulator said on Thursday, as Beijing looks to help stimulate innovation in the country's pharmaceutical sector.
The trial, set to take place in 10 regions, will allow research and development bodies to seek drug approvals, which are currently restricted to drug manufacturers, the China Food and Drug Administration said in a statement on its website.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”